Janux Therapeutics (JANX) Cash from Financing Activities (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Cash from Financing Activities data on file, last reported at $3.5 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 539.89% year-over-year to $3.5 million in Q1 2026; TTM through Mar 2026 was $7.9 million, a 97.97% decrease from a year earlier, with the FY2025 full-year figure at $4.9 million, down 99.31% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $3.5 million, up from $2.9 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for JANX reached as high as $386.6 million in Q4 2024 and fell as low as $1000.0 in Q1 2022.
• Historically, Cash from Financing Activities has averaged $48.9 million across 5 years, with a median of $1.3 million in 2023.
• Across the five-year window, Cash from Financing Activities plunged 100.0% in 2022 and jumped 157900.0% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at $191000.0 in 2022, then surged by 335.08% to $831000.0 in 2023, then jumped by 46428.28% to $386.6 million in 2024, then tumbled by 99.24% to $2.9 million in 2025, then advanced by 20.41% to $3.5 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $3.5 million in Q1 2026, $2.9 million in Q4 2025, and $493000.0 in Q3 2025.